Chlamydia often causes no noticeable symptoms, so many people may not know they have it. Learn why it is widely reported in the United States, how screening helps limit its spread, and why timely care matters for preventing complications such as infertility.

Multiple Choice

Which sexually transmitted infection is the most commonly reported in the United States?

Chlamydia is the most commonly reported sexually transmitted infection (STI) in the United States. It is particularly prevalent among adolescents and young adults, making it a significant public health concern. The high incidence of chlamydia is largely attributed to several factors, including the often asymptomatic nature of the infection, which can lead to a lack of awareness and subsequent untreated cases. Public health initiatives focus on screening and education to reduce transmission rates. Because chlamydia can cause serious complications if left untreated, including infertility in both men and women, its high reporting rate highlights the need for ongoing attention to STI prevention and awareness efforts.

Chlamydia: Why the Most Reported STI Often Goes Unnoticed

Chlamydia is the most commonly reported sexually transmitted infection in the United States. That distinction can sound surprising because many people with chlamydia have no symptoms at all. But that’s part of the story: an infection can spread quietly when someone feels well, doesn’t know they have it, and has no reason to seek care.

Chlamydia is caused by the bacterium Chlamydia trachomatis. It can infect the cervix, urethra, rectum, and other areas, and it may affect people of any gender. Young adults are especially affected, though age alone doesn’t determine someone’s risk. Understanding how the infection spreads, how it’s detected, and what can happen when it goes untreated helps explain why screening and clear, respectful health information matter.

“Most reported” doesn’t mean every infection is counted

Public health agencies track chlamydia because it is a nationally notifiable infection: laboratories and health departments report diagnosed cases under public health rules. Those reports are useful, but they don’t capture every infection in the country. Someone who is never tested, or whose infection is never diagnosed, won’t appear in the count.

So the number of reported cases is not a perfect measure of how many people have chlamydia. It reflects both the spread of infection and how much testing and reporting occur. A rise in reported cases may signal more infections, more screening, or a mix of both.

This distinction matters when comparing chlamydia with other sexually transmitted infections. The “most reported” label refers to documented cases in surveillance data, not necessarily to every infection that exists. Still, the high number of reported cases makes chlamydia a major public health concern.

The quiet infection

Many people with chlamydia have no noticeable symptoms. When symptoms do appear, they can be mild or easy to mistake for something else. A person with a cervix might notice unusual vaginal discharge, burning when urinating, bleeding between periods, or pain during sex. A person with a penis might have discharge from the penis, burning during urination, or pain or swelling in one or both testicles. Rectal infection can cause pain, discharge, or bleeding, but it may also cause no symptoms.

Symptoms aren’t a reliable way to tell whether someone has chlamydia. No symptoms doesn’t mean no infection—and the absence of discomfort can make testing less likely. This is one reason screening can find infections that might otherwise go unnoticed.

Chlamydia spreads through vaginal, anal, or oral sex with an infected person. It can also pass from a pregnant person to a baby during childbirth. Condoms and other barrier methods lower the chance of transmission when used correctly, though they don’t remove all risk. Honest conversations with partners and healthcare providers can help people make informed choices without shame or blame.

Why screening matters

Screening is especially important for groups with higher rates of infection, including sexually active adolescents and young adults. U.S. health guidance recommends regular screening for sexually active women under 25, as well as screening for older women with increased risk factors. Recommendations can differ based on a person’s age, anatomy, sexual history, pregnancy status, and local guidance, so a healthcare provider can help determine what makes sense.

Testing is usually straightforward. A clinician may use a urine sample or collect a swab from the area where infection is suspected. Depending on someone’s sexual history and symptoms, testing may include more than one site, such as the throat or rectum. That detail is worth discussing openly: a urine test alone may not detect an infection at another site.

Screening isn’t only about individual health. Finding an infection allows it to be treated and helps reduce the chance of passing it to others. Routine, nonjudgmental screening also makes sexual health care feel less like a special event and more like an ordinary part of looking after one’s health.

Treatment works—but timing counts

Chlamydia is curable with antibiotics. The specific medication depends on factors such as pregnancy status and a person’s medical needs; doxycycline is commonly recommended for nonpregnant adults, while other regimens may be used in pregnancy. A healthcare professional should select the treatment and explain how to take it.

It’s important to finish the prescribed medication, even if symptoms improve or were never present. People treated for chlamydia are generally advised to avoid sex for seven days after a single-dose treatment or until they have completed a seven-day course, and until their recent sex partners have been treated. Otherwise, someone can be reinfected—or pass the infection along before treatment has had time to work.

Recent partners need to be notified, tested, and treated as appropriate. Some health departments and clinics can help with partner notification, and in some places a clinician may provide medication for a partner without first examining them. Local rules vary. A follow-up test around three months after treatment is commonly recommended because repeat infection is frequent. This is different from testing immediately to check whether treatment worked; a test too soon can remain positive even after the infection has cleared.

Untreated infection can have lasting effects

When chlamydia isn’t treated, it can lead to serious complications. In people with a uterus, the infection can move into the reproductive organs and cause pelvic inflammatory disease (PID). PID may lead to chronic pelvic pain, infertility, or an ectopic pregnancy, in which a pregnancy develops outside the uterus. Some people have few symptoms while this damage is developing, which makes timely detection especially important.

In people with a penis, complications are less common but can include inflammation of the epididymis, the tube that carries sperm. Pain, swelling, and, rarely, fertility problems may follow. Chlamydia during pregnancy also matters: it can be passed to a baby during birth and may cause eye infection or pneumonia in the newborn.

These outcomes aren’t inevitable. The point is not to create fear, but to make the case for early care. A simple test and an effective course of antibiotics can prevent many complications.

A calmer, clearer approach to sexual health

Chlamydia’s high reported rate reflects a combination of widespread infection, frequent absence of symptoms, and the role of screening in finding cases. It’s a reminder that sexual health isn’t always something people can judge by how they feel. Testing, treatment, and partner care each play a part in slowing transmission and protecting long-term health.

For anyone who may have been exposed, has symptoms, or has a partner diagnosed with chlamydia, a healthcare provider or sexual health clinic can explain the next steps. Clear information and timely care go a long way—and there’s no need for shame in asking for either.